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Abstract:  Vascular  endothelial  dysfunction  induced  by  oxidative  stress  has  been 
demonstrated to be the initiation step of atherosclerosis (AS), and flavonoids may play an 
important role  in  AS prevention and therapy.  Twenty-three  flavonoids categorized  into 
flavones,  flavonols,  isoflavones,  and  flavanones,  all  with  4-oxo-pyronenucleus,  were 
examined  for  what  structural  characteristics  are  required  for  the  inhibitory  effects  on 
endothelial  dysfunction  induced  by  oxidized  low-density  lipoprotein  (oxLDL).  Human 
vascular endothelial cells EA.hy926 were pretreated with different 4-oxo-flavonoids for  
2  hs,  and  then  exposed  to  oxLDL  for  another  24  hs.  Cell  viability  and  the  level  of 
malondialdehyde (MDA), nitric oxide (NO) and soluble intercellular adhesion molecule-1 
(sICAM-1) were measured, respectively. Then, correlation analysis and paired comparison 
were  used  to  analyze  the  structure–activity  relationships.  Significant  correlations  were 
observed between the number of –OH moieties in total or in B-ring and the inhibitory 
effectson  endothelial  dysfunction.  Furthermore,  3',4'-ortho-dihydroxyl  on  B-ring,  
3-hydroxyl on C-ring and 2,3-double bondwere correlated closely to the inhibitory effects 
of flavonolson cell viability decrease and lipid peroxidation. 5,7-meta-dihydroxyl group on 
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A-ring  was  crucial  for  the  anti-inflammatory  effects  of  flavones  and  isoflavones  in 
endothelial cells. Moreover, the substituted position of B-ring on C3 rather than C2 was 
important  for  NO  release.  Additionally,  hydroxylation  at  C6  position  significantly 
attenuated  the  inhibitory  effects  of  4-oxo-flavonoids  on  endothelial  dysfunction. 
Our  findings  indicated  that  the  effective  agents  in  inhibiting  endothelial  dysfunction 
include myricetin, quercetin, luteolin, apigenin, genistein and daidzein. Our work might 
provide  some  evidence  for  AS  prevention  and  a  strategy  for  the  design  of  novel  AS  
preventive agents. 
Keywords:  flavonoids;  endothelial  dysfunction;  oxidized  low-density  lipoprotein; 
structure-activity analysis; atherosclerosis; reactive oxygen species 
 
1. Introduction  
Atherosclerosis (AS) is a multifactorial disease of the vessel wall involving lipid accumulation, 
thrombogenic components, cell death and inflammatory responses in the arterial wall, causing heart 
disease and stroke [1]. High plasma level of low-density lipoprotein (LDL) is closely correlated with 
accelerated atherogenesis [2,3]. LDL could be oxidatively modified to be oxidized LDL (oxLDL) by 
transition metal ions such as copper ion (Cu
2+), or by inorganic oxidants such as H2O2. oxLDL is more 
important  than  native-LDL  for  atherogenesis,  mainly  leading  to  vascular  endothelial  dysfunction,  
foam  cell  formation  and  smooth  cell  proliferation  [4].  Endothelial  dysfunction  is  characterized  by  
a  shift  of  the  actions  of  the  endothelium  toward  increased  lipid  oxidation,  reduced  vasodilation,  
a proinflammatory state and prothrombic properties. Therefore, endothelial dysfunction induced by 
oxLDL has been known to be a key event in the development of AS and predates clinically obvious 
vascular pathology by many years [5,6]. 
Flavonoids are important phytonutrient components distributed in a wide range of fruits, vegetables, 
nuts and beverages, including wine and tea. Roughly speaking, there are more than 4000 types of 
flavonoids. The structure of the flavonoids is based on the flavonoid nucleus (Figure 1a,b), which 
consists of three phenolic rings referred to as the A, B, and C rings. The benzene ring A is condensed 
with a six-member ring (C-ring), which in the 2-position carries a phenyl benzene ring (B-ring) as a 
substituent.  Ring  C  may  be  a  heterocyclic  pyran,  which  yields  anthocyanins  (Figure  1c),  or  
4-oxo-pyrone, which yields flavones (Figure 1d), flavonols (Figure 1e), flavanones (Figure 1f) and 
isoflavones (Figure 1g) [7]. Epidemiological studies have revealed an  inverse association  between 
dietary flavonoids intake and the occurrence of cardiovascular disease, such as AS [8]. This raises the 
possibility that flavonoids may act as a lead compound for the development of therapeutic agents, 
which can be used in AS prevention and therapy. Int. J. Mol. Sci. 2011, 12                     
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Figure  1.  The  classification  and  structure  of  the  flavonoids:  (a)  flavan  nucleus; 
(b) 4-oxo-flavonoid nucleus; (c) anthocyanidins; (d) flavones; (e) flavonols; (f) flavanones 
and (g) isoflavones. 
 
Since  different  flavonoids  might  have  different  roles  in  endothelial  cells,  the  structure–activity 
relationships  of  flavonoids  have  become  the  subject  of  many  investigations  [9,10].  Certain  
flavonoids  such  as  quercetin  are  potent  in  scavenging  radicals,  while  genistein  could  ameliorate 
endothelium-dependent  vasorelaxation  [11,12].  In  our  previous  study,  we  firstly  reported  the 
differences of anthocyanins, one subclass of flavonoids with a  flavan nucleus,  in the inhibition of 
oxLDL-induced endothelial injury, and clarified the main structural requirements for the inhibitory 
effects  [13].  However,  there  are  large  numbers  of  flavonoids,  in  particular  flavonoids  with  
4-oxo-pyronenucleus widely distributed in the plant foods. Few investigations have examined what 
structural  characteristics  are  required  for  the  inhibitory  effects  on  endothelial  dysfunction.  
In the present study, we screened a total of 23 flavonoids (Table 1) with a 4-oxo-pyrone nucleus, 
categorized into flavones, flavonols, flavanones and isoflavones, and compared the different effects on 
the  cell  viability,  lipid  oxidation,  secretory  function  and  inflammatory  reaction  in  oxLDL-induced 
endothelial cells. Our work provides evidence that certain chemical  structures of 4-oxo-flavonoids 
were crucial for the inhibitory effects on endothelial dysfunction. Int. J. Mol. Sci. 2011, 12                     
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Table 1.Molecular characteristics of 23 4-oxo-flavonoids tested in our study. 
No.  Chemicals  Source 
B-ring 
 
C-ring 
 
A-ring  2,3-double 
bond 
The number of −OH 
C2'  C3'  C4'  C5'  C6'  C2  C3  C5  C6  C7  C8  In total  A-ring  B-ring  C-ring 
flavones:                                   
1  flavone  Sigma  −H  −H  −H  −H  −H  B-ring  −H  −H  −H  −H  −H  √  0  0  0  0 
2  chrysin  Sigma  −H  −H  −H  −H  −H  B-ring  −H  −OH  −H  −OH  −H  √  2  2  0  0 
3  apigenin  Sigma  −H  −H  −OH  −H  −H  B-ring  −H  −OH  −H  −OH  −H  √  3  2  1  0 
4  luteolin  Sigma  −H  −OH  −OH  −H  −H  B-ring  −H  −OH  −H  −OH  −H  √  4  2  2  0 
5  6-hydroxyflavone  Sigma  −H  −H  −H  −H  −H  B-ring  −H  −H  −OH  −H  −H  √  1  1  0  0 
6  baicalein  Sigma  −H  −H  −H  −H  −H  B-ring  −H  −OH  −OH  −OH  −H  √  3  3  0  0 
7  7-hydroxyflavone  Sigma  −H  −H  −H  −H  −H  B-ring  −H  −H  −H  −OH  −H  √  1  1  0  0 
isoflavones:                                   
8  genistein  Sigma  −H  −H  −OH  −H  −H  −H  B−ring  −OH  −H  −OH  −H  √  3  2  1  0 
9  daidzein  Sigma  −H  −H  −OH  −H  −H  −H  B−ring  −H  −H  −OH  −H  √  2  1  1  0 
flavanones:                                   
10  hesperetin  Sigma  −H  −OH  −OCH3  −H  −H  B-ring  −H  −OH  −H  −OH  −H  −  3  2  1  0 
11  flavanone  Sigma  −H  −H  −H  −H  −H  B-ring  −H  −H  −H  −H  −H  −  0  0  0  0 
12  naringenin  Sigma  −H  −H  −OH  −H  −H  B-ring  −H  −OH  −H  −OH  −H  −  3  2  1  0 
13  2'-hydroxyflavanone  Sigma  −OH  −H  −H  −H  −H  B-ring  −H  −H  −H  −H  −H  −  1  0  1  0 
14  4'-hydroxyflavanone  Sigma  −H  −H  −OH  −H  −H  B-ring  −H  −H  −H  −H  −H  −  1  0  1  0 
flavonols:                                   
15  galangin  Sigma  −H  −H  −H  −H  −H  B-ring  −OH  −OH  −H  −OH  −H  √  3  2  0  1 
16  morin  Sigma  −OH  −H  −OH  −H  −H  B-ring  −OH  −OH  −H  −OH  −H  √  5  2  2  1 
17  myricetin  Sigma  −H  −OH  −OH  −OH  −H  B-ring  −OH  −OH  −H  −OH  −H  √  6  2  3  1 
18  fisetin  Sigma  −H  −OH  −OH  −H  −H  B-ring  −OH  −H  −H  −OH  −H  √  4  1  2  1 
19  geraldol  Sigma  −H  −OCH3  −OH  −H  −H  B-ring  −OH  −H  −H  −OH  −H  √  3  1  1  1 
20  quercetin  Sigma  −H  −OH  −OH  −H  −H  B-ring  −OH  −OH  −H  −OH  −H  √  5  2  2  1 
21  gossypin  Sigma  −H  −OH  −OH  −H  −H  B-ring  −OH  −OH  −H  −OH  O-glucoside  √  5  2  2  1 
22  3,6-dihydroxyflavone  Sigma  −H  −H  −H  −H  −H  B-ring  −OH  −H  −OH  −H  −H  √  2  1  0  1 
23  3,7-dihydroxyflavone  Sigma  −H  −H  −H  −H  −H  B-ring  −OH  −H  −H  −OH  −H  √  2  1  0  1 
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2. Results 
In this work, we selected 23 kinds of 4-oxo-flavonoids, including seven flavones, two isoflavones, 
five  flavanones  and  nine  flavonols,  to  evaluate  their  effects  on  oxLDL-induced  endothelial 
dysfunction. The compounds name and structure characteristics are presented in Table 1 according to 
their  subgroup  classification.  The  inhibitory  effects  of  flavonoids  on  oxLDL-induced  endothelial 
dysfunction  were  evaluated  by  measuring  cell  viability  and  the  level  of  malondialdehyde  (MDA), 
nitric oxide (NO) and soluble intercellular adhesion molecule-1 (sICAM-1). Our results suggested that 
the inhibitory effects of different flavonoids on endothelial dysfunction were differential (Table 2 and 
Figure 2). All flavanones, structurally resembling flavones and flavonols containing a 2,3-double bond 
showed no notable effect on cell viability and the level of MDA, NO and sICAM-1 in oxLDL-induced 
endothelial cells at any treated concentration. However, most flavonols tested in our study, such as 
morin,  myricetin, fisetin, and quercetin, demonstrated a significant effect in all measurements with 
concentration  of  more  than  40μM.  Two  isoflavones,  genistein  and  daidzein  showed  a  dominantly 
enhanced effect on NO release, suggesting a particular effect on the endothelial secretory function and 
endothelium-dependent vasorelaxation. Luteolin and apigenin, belonging to the flavones, were prone 
to inhibit sICAM-1 generation and also promote NO release. Furthermore, our data showed that a few 
flavonoids,  such  as  6-hydroxyflavone  and  3,6-dihydroxyflavone,  exacerbated  the  oxLDL-induced 
endothelial  dysfunction,  suggesting  a  potentially  negative  effects  on  endothelial  dysfunction. 
Additionally,  significant  correlations  were  observed  between  the  effects  of  4-oxo-flavonoids  on 
oxLDL-induced cell  viability and MDA generation (r = −0.812, P < 0.01), cell  viability and NO 
release (r = 0.657, P < 0.01), cell viability and sICAM-1 (r = −0.677, P < 0.01), MDA generation and 
NO release (r = −0.743, P < 0.01), MDA generation and sICAM-1 (r = 0.717, P < 0.01); NO release 
and sICAM-1 (r = 0.810, P < 0.01), respectively. 
We performed the correlation analysis and paired comparison to elucidate the structure–activity 
relationship of 4-oxo-flavonoids in inhibiting endothelial dysfunction. Figure 3 shows that the number 
of –OH groups of the tested 4-oxo-flavonoids in total (Figure 3A) and in B-ring (Figure 3B) ranged 
from  0–6  and  0–3,  respectively.  Using  Pearson’s  Correlation  Analysis,  we  found  a  significant 
correlation between the number of –OH moities in total and the effect of 4-oxo-flavonoids (at 40 μM) 
on  cell  viability  (correlation  coefficient  square  (R
2  =  0.731,  P  <0.01),  MDA  level  (R
2  =  0.645,  
P < 0.01), NO level (R
2 = 0.359, P < 0.01) and sICAM-1 level (R
2 = 0.379, P < 0.01). Moreover, 
significant linear relationships were also observed between the number of −OH moieties in B-ring and 
the  effect  of  4-oxo-flavonoids  on  cell  viability  (R
2  =  0.485,  P  <  0.01)  and  the  level  of  MDA 
(R
2 = 0.768, P < 0.01), NO (R
2 = 0.406, P < 0.01) and sICAM-1 (R
2 = 0.424, P < 0.01), respectively. 
The results suggested that the inhibitory effects of 4-oxo-flavonoids on the oxLDL-induced endothelial 
dysfunction were enhanced with the increase of –OH moieties in total or in B-ring, respectively. Int. J. Mol. Sci. 2011, 12                     
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Table  2.  Effect  of  4-oxo-flavonoids  with  different  concentrations  on  oxLDL-induced 
endothelial viability. EA.hy926 cells were pretreated with different 4-oxo-flavonoids at a 
series of concentration (5, 10,  20, 40 and 80 μM)  for 2 hs and exposed to oxLDL of 
100 μg/mL for another 24 hs. The optical density was measured at 450 nm and the values 
were determined as the percentage of the control group. 
# P < 0.05, 
## P < 0.01, compared 
with control group; * P < 0.05, ** P < 0.01, compared with oxLDL group. 
Groups 
Cell viability (% of control) 
  5 μM  10 μM  20 μM  40 μM  80 μM 
Control  100.00           
0.2% DMSO  106.36 ± 10.32           
100 μg/mL 
oxLDL 
47.11± 5.19 
##           
flavones: 
 
         
flavone  47.76 ± 4.77  48.27 ± 5.91  45.22 ± 5.50  45.88 ± 7.92  40.65 ± 6.53 
chrysin  48.08 ± 3.83  47.29 ± 8.56  53.98± 5.64  58.73 ± 4.16  45.12 ± 2.94 
apigenin  53.86 ± 2.89  50.67 ± 6.25  54.64± 8.36  48.73 ± 5.08  42.79 ± 5.35 
luteolin  55.96 ± 1.99  59.48 ± 6.32  61.04 ± 6.74 *  68.27 ± 8.22 *  76.44 ± 4.46 ** 
6-hydroxyflavone  46.99 ± 7.92  43.90 ± 4.19  40.60 ± 6.04  35.34 ± 6.59  29.51 ± 4.84 
baicalein  48.62 ± 2.28  50.25 ± 6.87  57.17± 6.38  65.81 ± 4.90 *  57.76 ± 5.51 
7-hydroxyflavone  50.34 ± 3.31  49.12 ± 8.92  44.46 ± 9.43  40.47 ± 2.32  33.23 ± 3.36 
isoflavones:           
genistein  51.15 ± 2.72  46.53 ± 6.70  52.81± 4.68  56.03 ± 7.71  43.46 ± 4.65 
daidzein  47.88 ± 4.22  47.94 ± 8.29  46.85± 11.10  53.94 ± 6.72  35.38 ± 9.70 
flavanones:           
hesperetin  49.72 ± 3.25  47.45 ± 3.03  57.32± 4.29  53.49 ± 2.89  45.89 ± 6.56 
flavanone  44.69 ± 5.27  48.48 ± 6.40  42.94± 4.56  38.20 ± 5.77  34.37 ± 3.31 
naringenin  49.47 ± 3.18  49.41 ± 7.63  54.10± 4.90  51.52 ± 6.26  40.41 ± 6.79 
2'-
hydroxyflavanone 
49.21 ± 3.02  51.41 ± 6.40  44.29± 3.01  45.51 ± 11.98  41.70 ± 6.59 
4'-
hydroxyflavanone 
51.64 ± 6.31  54.01 ± 5.54  49.50± 10.23  47.08 ± 3.38  43.23 ± 3.81 
flavonols:           
galangin  52.15 ± 3.57  56.59 ± 3.56  62.29± 4.35 *  67.78 ± 5.69 *  68.56 ± 2.24 * 
morin  53.24 ± 3.51  54.00 ± 7.73  59.72± 3.85  65.37 ± 11.06 *  71.60 ± 4.45 ** 
myricetin  53.07 ± 2.00  60.19 ± 5.12  68.41± 4.60 *  73.26 ± 3.61 **  82.58 ± 3.67 ** 
fisetin  51.66 ± 3.97  58.92 ± 3.44  64.49± 8.1 *  71.22 ± 4.73 **  79.40 ± 5.55 ** 
geraldol  49.35 ± 3.52  50.63 ± 7.49  45.57± 2.57  55.81 ± 2.60  40.24 ± 3.75 
quercetin  50.75 ± 2.13  59.49 ± 7.71  66.32± 6.4 *  73.63 ± 3.87 **  81.53 ± 6.18 ** 
gossypin  48.99 ± 3.27  58.15 ± 3.34  65.31± 6.5 *  67.87 ± 4.50 *  78.78 ± 4.42 ** 
3,6-
dihydroxyflavone 
50.66 ± 6.11  50.11 ± 5.70  46.15± 7.99  39.38 ± 6.14  34.07 ± 4.31 
3,7-
dihydroxyflavone 
45.74 ± 4.81  50.57 ± 7.01  42.87± 4.28  42.42 ± 4.67  39.12 ± 3.03 Int. J. Mol. Sci. 2011, 12                     
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Figure 2. Effect of different 4-oxo-flavonoids of 40 μM on oxLDL-induced endothelial 
viability (A) and the level of MDA (B), NO (C) and sICAM-1 (D). EA.hy926 cells were 
pretreated with different 4-oxo-flavonoids of 40 μM, and exposed to oxLDL of 100 μg/mL 
for  another  24  hs.  Cell  viability  was  measured  by  CCK-8  assay  and  the  values  were 
determined as the percentage of the control group. The level of MDA, NO, and sICAM-1 
were determined by the corresponding detecting kits. All of the data are expressed as the 
means ± S.D. 
# P < 0.05, 
## P < 0.01,  compared with the control group; * P < 0.05, 
** P < 0.01, compared with the oxLDL group. 
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Figure 3. Correlation between the number of –OH groups of 4-oxo-flavonoids and the 
inhibitory effects on oxLDL-induced endothelial dysfunction. In the scatter plot, the X axis 
(horizontal axis) represents the number of –OH groups of flavonoids in total (A) or in  
B-ring; and (B), and the Y axis (vertical axis) represents the measurements of cell viability, 
MDA level NO level and sICAM-1 level, respectively. The overlay scatter plots represent 
23  flavonoids  in  different  experiments,  respectively.  Data  were  analyzed  by  Pearson’s 
correlation coefficient (r) and Fisher’s r to z (p) about 23 flavonoids. * P < 0.01. 
 
As shown in Table 3, we performed the paired comparison analysis to investigate the effect of 
different  substitutions  on  ring-B  (Table  3a),  A  (Table  3b)  and  C  (Table  3c),  the  presence  of  
2,3-double bond (Table 3d) and the substituted position of B-ring (Table 3e) of 4-oxo-flavonoids on 
oxLDL-induced endothelial dysfunction. In general, the results demonstrated that a 3',4'-ortho-dihydroxyl 
on B-ring, a 3-hydroxyl on C-ring and 2,3-double bond and a 5,7-meta-dihydroxyl on A-ring were all 
required for the inhibitory effects on endothelial dysfunction. However, the potential roles of these 
chemical  characteristics  of  4-oxo-flavonoids  in  relation  to  the  inhibitory  effects  on  endothelial 
dysfunction  might be differential.  Flavonols and flavones with a 3',4'-ortho-dihydroxyl were  much 
stronger  in  promoting  cell  viability  and  NO  release  as  well  as  decreasing  MDA  and  sICAM-1 
generation, which implied the crucial roles of a 3',4'-ortho-dihydroxyl group (Table 3b). Consistent 
with this finding, we found that quercetin (3',4',3,5,7-pentahydroxyflavone) was more efficient than 
galangin  (3,5,7-trihydroxyflavone)  (Figure  4A1),  luteolin  (3',4',5,7-tetrahydroxyflavone)  was  more 
active thanchrysin (5,7-dihydroxyflavone) (Figure 4A2), and fistin (3',4',3,7-tetrahydroxyl) suppressed 
the geraldol (3'-methoxyl, 4',3,7-trihydroxyflavone) activity. Interestingly, the simultaneous presence 
of three hydroxyl groups at positions 3', 4' and 5' in flavonols (e.g., myricetin vs. quercetin) did not 
significantly  improve the  inhibitory effect on endothelial  injury (Figure 4A3). Moreover, favonols 
were superior to the flavanones with the same substituents in inhibiting endothelial dysfunction, due  
to the presence of 2,3-double bond (Table 3d, Figure 4D1,D2). Quercetin was much stronger than 
luteolin  in  decreasing  MDA  and  sICAM-1  generation  and  enhancing  NO  release,  suggesting  the 
potential roles of 3-hydroxyl group (Table 3c, Figure 4C1,C2). Additionally, a 5,7-meta-dihydroxyl on 
A-ring  might  be  correlated  closely  to  the  inhibitory  effects  on  sICAM-1  generation  (Table  3b,  Int. J. Mol. Sci. 2011, 12                     
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Figure 4B1,B2). However, adding another hydroxyl group in the A ring at 6-position significantly 
decreased the activity for chrysin, highlighting the importance of 5,7-meta-dihydroxyl groups in the  
anti-inflammatory activity (Table 3b and Figure 4D3). Therefore, fisetin with merely a –OH on C7 of 
A-ring,  was  less  effective  to  quercetin.  Interestingly,  6-hydroxyflavone  and  3,6-dihydroxyflavone, 
both  of  which  are  structurally  hydroxylated  on  C6  of  A-ring,  obviously  aggravated  endothelial 
dysfunction. Thus, baicalein, which is structurally identical to chrysin with a 5,7-meta-dihydroxyl but 
possess  an  another  hydroxyl  group  on  C6  position  of  A-ring,  was  ineffectual.  Both  isoflavones 
(genistein and daidzein) showed significant effects on stimulating the NO release. This result revealed 
that the substituted position of B-ring at C3 rather than that at C2 of B-ring greatly increased the effect 
of 4-oxo-flavonoids on endothelial secretory activity (Table 3e and Figure 4E). 
Table 3. Influence of changing substituents of 4-oxo-flavonoids on cell viability and the 
level  of  MDA,  NO  and  sICAM-1  in  oxLDL-induced  EA.hy926  cells.
  *
  P  <  0.05,  
** P < 0.01, A vs. B in paired comparison; ↑: A < B; ↓: A > B. 
Paired comparison  Cell 
viability 
MDA
level 
NO 
level 
sICAM-
1level  A  B 
(a)  B-ring             
  flavanone 
2'-hydroxyflavanone  
(2'-hydroxyl) 
↑  ↓  ↓  ↑ 
  morin(2',4'-dihydroxyl)  quercetin(3',4'-dihydroxy)  ↑ 
*  ↓ 
*  ↑ 
*  ↓ 
* 
 
geraldol (3'-methoxy, 4'-
hydroxyl) 
fistin (3',4'-dihydroxyl)  ↑ 
**  ↓ 
*  ↑ 
**  ↓ 
  apigenin (4'-hydroxyl)  luteolin (3',4'-dihydroxyl)  ↑ 
**  ↓ 
*  ↓  ↑ 
  3,7-dihydroxyflavone  fistin (3',4'-dihydroxyl)  ↑ 
**  ↓ 
**  ↑ 
**  ↓ 
** 
  flavanone 
4'-hydroxyflavanone  
(4'-hydroxyl) 
↑  ↓ 
*  ↑  ↓ 
  chrysin  apigenin (4'-hydroxyl)  ↓  ↓ 
*  ↑  ↓ 
* 
  chrysin  luteolin (3',4'-dihydroxyl)  ↑ 
*  ↓ 
*  ↑  ↓ 
* 
  galangin  morin (2',4'-dihydroxyl)  ↓  ↓  ↓  ↓ 
  galangin 
myricetin 
(3',4',5'-trihydroxyl) 
↑ 
*  ↓ 
**  ↑ 
*  ↓ 
** 
  galangin  quercetin (3',4'-dihydroxyl)  ↑ 
*  ↓ 
**  ↑ 
*  ↓ 
* 
  morin (2',4'-dihydroxyl) 
myricetin 
(3',4',5'-trihydroxyl) 
↑ 
*  ↓ 
*  ↑ 
*  ↓ 
** 
  morin (2',4'-dihydroxyl)  quercetin (3',4'-dihydroxyl)  ↑ 
*  ↓ 
*  ↑ 
**  ↓ 
** 
  3,7-dihydroxyflavone  fistin (3',4'-dihydroxyl)  ↑ 
**  ↓ 
**  ↑ 
**  ↓ 
* 
  3,7-dihydroxyflavone 
geraldol 
(3'-methoxyl, 4'-hydroxyl) 
↑  ↓
*  ↑  ↓ 
 
chrysin (2',4' -
dihydroxyl) 
luteolin (3',4'-dihydroxyl)  ↑ 
*  ↓ 
**  ↑  ↓ 
* 
 
quercetin (3',4'-
dihydroxyl) 
myricetin 
(3',4',5'-trihydroxyl) 
↓  ↓  ↑  ↑ Int. J. Mol. Sci. 2011, 12                     
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Table 3. Cont. 
Paired comparison  Cell 
viability 
MDA
level 
NO 
level 
sICAM-
1level  A  B 
(b)  A-ring             
  flavone  chrysin (5,7-dihydroxyl)  ↑  ↓  ↑ 
**  ↓ 
  flavone 
6-hydroxyflavone  
(6-hydroxyl) 
↓ 
*  ↑ 
*  ↓ 
*  ↑ 
* 
  flavone  baicalein (5,6,7-trihydroxyl)  ↑ 
*  ↑  ↓ 
*  ↓ 
  flavone 
7-hydroxyflavone  
(7-hydroxyl) 
↓  ↓  ↓  ↑ 
  chrysin (5,7-dihydroxyl)  baicalein (5,6,7-trihydroxyl)  ↑ 
*  ↑ 
*  ↓ 
**  ↑ 
  chrysin (5,7-dihydroxyl) 
7-hydroxyflavone  
(7-hydroxyl) 
↓ 
*  ↓  ↓ 
**  ↑ 
* 
  chrysin (5,7-dihydroxyl) 
6-hydroxyflavone  
(6-hydroxyl) 
↓ 
**  ↑ 
**  ↓ 
**  ↑ 
** 
  genistein  daidzein  ↓  ↑  ↓  ↑ 
* 
  fistin (7-hydroxyl)  quercetin(5,7-dihydroxyl)  ↑  ↓  ↑  ↓ 
** 
  fistin (7-hydroxyl) 
gossypin (5,7-dihydroxyl, 
8-O-glucoside) 
↓  ↓  ↓ 
**  ↑ 
 
6-hydroxyflavone (6-
hydroxyl) 
baicalein (5,6,7-trihydroxyl)  ↑ 
**  ↓  ↓  ↓
* 
 
6-hydroxyflavone (6-
hydroxyl) 
7-hydroxyflavone  
(7-hydroxyl) 
↑  ↓ 
*  ↓  ↓ 
* 
 
quercetin (5,7-
dihydroxyl) 
gossypin (5,7-dihydroxyl,  
8-O-glucoside) 
↓  ↑  ↓ 
**  ↑ 
** 
 
3,6-dihydroxyflavone 
(6-hydroxyl) 
3,7-dihydroxyflavone  
(7-hydroxyl) 
↑  ↓  ↑ 
*  ↓ 
* 
(c)  C-ring             
  chrysin  galangin (3-hydroxyl)  ↑ 
*  ↓  ↑  ↓ 
* 
  luteolin  quercetin(3-hydroxyl)  ↑  ↓ 
*  ↑ 
*  ↓ 
** 
 
7-hydroxyflavone (7-
hydroxyl) 
3,7-dihydroxyflavone  
(3,7-dihydroxyl) 
↑  ↑  ↑  ↑ 
(d)  2,3-double bond             
  flavanone  flavone (2,3-double bond)  ↑ 
*  ↓  ↓  ↓ 
* 
  naringenin  apigenin (2,3-double bond)  ↓  ↓
 *  ↑ 
*  ↓ 
** 
(e) 
Substituted position of 
B-ring 
           
  apigenin (C2)  genistein (C3)  ↑  ↓  ↑ 
*  ↑ 
* 
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Figure  4.  Effect  of  structural  modificationsof  4-oxo-flavonoids  on  the  inhibition  
of  endothelial  dysfunction  by  3',4'-ortho-dihydroxyl  group  (A1,  A2  and  A3),  
5,7-meta-dihydroxyl group (B1, B2 and B3), 3-hydroxyl group (C1 and C2), 2,3-double 
bond (D1 and D2) and the substituted position of B-ring (E). 
 
Thus,  we  demonstrated  that  flavonols  were  prone  to  improve  cell  viability  and  inhibit  lipid 
peroxidation  induced  by  oxidative  stress  in  endothelial  cells  correlated  with  the  presence  of  a  
3',4'-ortho-dihydroxyl, a 3-hydroxyl and 2,3-double bond. While flavones with a 5,7-meta-dihydroxyl 
and isoflavones with a B-ring on C3 position were effectual to affect the inflammatory reaction and the 
secretory  function  in  endothelial  cells,  respectively.  Flavanone,  without  any  typical  characteristics 
above, showed no dominant effect. Furthermore, flavonoids such as myricetin, quercetin, genistein, 
daidzein, apigenin and luteolin were found with significant activity in inhibiting endothelial dysfunction. Int. J. Mol. Sci. 2011, 12                     
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3. Experimental Section 
3.1. Reagents 
Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were both purchased 
from Gibco Company (Gibco, NY, USA). Cell Counting Kit (CCK-8) was purchased from Dojindo 
Laboratories  (Kumamoto,  Japan).  MDA  and  NO  assay  kits  were  both  purchased  from  Nanjing 
Jiancheng  Bioengineering  Institute  (Nanjing,  China).  A  total  of  23  4-oxo-flavonoids  (Table  1), 
Enzyme-linked immunosorbent assay (ELISA) kit for sICAM-1 was obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Flavonoids were dissolved in dimethyl sulfoxide (DMSO), with the final culture 
concentration of DMSO ≤ 0.2%. 
3.2. Oxidation of Low-Density Lipoprotein  
Human LDL was isolated from serum of 15 healthy donors (35.3 ± 6.28 years old; males/female: 
8/7). This work was approved by Ethics Committee of Third Military Medical University, and each of 
the participants provided written informed consent. The oxLDL was prepared according to the method 
of Sternberg [14]. A 10 mg sample of LDL was dialyzed against Tris/NaCl buffer (50 mM Tris in 
0.15 M NaCl, pH 8.0) to remove the EDTA. Afterwards, Tris/NaCl buffer was added to the dialyzed 
LDL to adjust the protein concentration to 30 mg/mL, then, 1 mL of 10 μM CuSO4 was added to 1 mL 
of dialyzed LDL. Oxidation at 37 °C for a period of 18 hs was followed by the addition of 300 μM 
EDTA to stop the reaction. The oxLDL was again dialyzed at 4 °C with Tris/NaCl buffer, filtered with 
a  0.22  μm  filter,  and  stored  in  nitrogen  at  4  °C.  Oxidation  was  monitored  by  estimation  of 
thiobarbituric acid reactive substances (TBARS) using  malondialdehyde assay kit according to the 
manufacturer’s instructions. 
3.3. Cell Culture  
Human  vascular  endothelial  cell  line  EA.hy926  was  purchased  from  American  Type  Culture 
Collection (ATCC). The cells were maintained in DMEM medium containing 100 U/mL penicillin, 
100 μg/mL streptomycin and 10% FBS at 37 °C under a humidified atmosphere with 5% CO2. 
3.4. Cell Viability Measurement 
CCK-8 detecting kit was used to measure cell viability as previously described [15]. EA.hy926 cells 
were seeded in 96-well microplate at a density of 1 × 10
4 cells/well. The cells were pretreated for 2 hs 
with different 4-oxo-flavonoids at a series of concentration (5, 10, 20, 40 and 80 μM) and were then 
exposed to 100 μg/mL oxLDL for another 24 hs. Control and solvent control groups were treated with 
culture medium and medium with 0.2% DMSO, respectively. Subsequently, CCK-8 (20 μL/well) was 
added  to  the  cells,  and  the  plate  was  incubated  at  37°C  for  2  hs.  Viable  cells  were  counted  by 
absorbance measurements with a monochromator microplate reader (SafireⅡ, Tecan, Switzerland) at  
a wavelength of 450 nm. The optical density (OD) 450 value was proportional to the degree of cell 
viability. Cell viability in the control group was set as 100%, and the cell viability in the other groups 
was determined as the percentage of the control group.  Int. J. Mol. Sci. 2011, 12                     
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3.5. Determination of MDA, NO and sICAM-1 Level 
EA.hy926 cells were pretreated with different 4-oxo-flavonoids at a concentration of 40 μM for 2 
hs, and then the cells were exposed to 100 μg/mL oxLDL for another 24 hs. The supernatant was 
collected from each well, and MDA, NO and sICAM-1 were measured with the corresponding assay 
kit  according  to  the  manufacturer’s  instructions,  respectively.  Briefly,  the  MDA  content  in 
supernatants was measured by TBARS as previously described, and the optical density was measured at 
532 nm [16]. MDA generated by acid hydrolysis of tetra-ethoxy-propane was used as a standard. NO 
in the supernatants was detected by measuring the concentration of nitrites (NO2
−) and nitrates (NO3
−), 
stable end products of NO at the wavelengths of 550 nm. Concentration of sICAM-1 in supernatants 
was determined by using human sICAM-1 ELISA kit. Absorbance of each well was determined within  
30 mins using a Microplate Reader (Biotek, Winooski, VT) at 450nm and each sample value (ng/L) 
were calculated from the standard curve. All measurements in the control group were set as 100%, and 
the measurements in the other groups were determined as the percentage of the control group.  
3.6. Structure-Activtity Relationship Analysis 
Based on the measurements of cell viability, MDA level, NO level and sICAM-1 level, Pearson 
Correlation  Assay  was  used  to  determine  the  correlation  of  all  measurements.  Meanwhile,  paired 
comparison  was  carried  out  by  Turkey-Kramer  assay  to  elucidate  the  structural  requirements  of  
4-oxo-flavonoids in relation to inhibition of endothelial dysfunction.  
3.7. Statistical Analysis  
The results were shown as mean ± S.D. Statistical analysis was performed by one-way analysis of 
variance. P < 0.05 was considered as statistically significant, and Tukey-Kramer was applied as post-hoc 
test if P < 0.05. The correlation between groups was evaluated by Pearson’s Correlation Analysis. 
4. Discussion 
In  the  present  study,  we  analyzed  the  effect  of  23  structurally  related  4-oxo-flavonoids  on  
oxLDL-induced endothelial dysfunction, an early event in the development of AS. We systematically 
analyzed the correlations between the structure characteristics of flavonoids and their different effects 
on oxidative stress-induced endothelial dysfunction.  This study  is one of  very  few that have used 
twenty-three  representative  4-oxo-flavonoids  categorized  into  four  groups,  flavones,  isoflavones, 
flavanones and  flavonols that are achievable  following  ingestion of  flavonoids-rich  foods, such as 
beans,  fruits,  vegetables  and  cereals.  Generally,  we  have  found  that  the  inhibitory  effects  of 
4-oxo-flavonoids on oxLDL-induced endothelial dysfunction were significantly correlated with the 
number  of  –OH  in  total  and  in  B-ring.  The  presence  of  a  3',4'-ortho-dihydroxyl  on  B-ring,  
a  3-hydroxyl  on  C-ring  and  a  2,3-double  bond  of  C-ring  appeared  to  be  the  main  structural 
requirements for the antioxidant activity, while a 5,7-meta-dihydroxyl on A-ring was correlated to the  
anti-inflammatory capacity of 4-oxo-flavonoids. Isoflavones, which possess a B-ring substituted on C3 
rather  than  C2  position  of  C-ring,  could  dominantly  enhance  NO  release  in  endothelial  cells, 
suggesting that the substituted position of B-ring might greatly influence the secretory function of Int. J. Mol. Sci. 2011, 12                     
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endothelial  cells (Figure 5). Additionally,  hydroxylation at C6 position significantly  attenuated the 
inhibitory  effects  of  4-oxo-flavonoids  on  endothelial  dysfunction.  This  is  the  first  report  of  the 
structural  requirements  of  4-oxo-flavonoids  in  inhibiting  endothelial  dysfunction  induced  by 
oxidative stress. 
Figure  5.  Schematic  representation  of  the  chemical  requirements  of  4-oxo-flavonoids 
(flavones, flavanones, flavonols and isoflavones) for inhibition of endothelial dysfunction. 
 
Recent studies emphasize the role of oxLDL in the pathogenesis of AS and showed that an elevated 
level of LDL is one of the most important risk factors for AS and cardiovascular morbidity [17,18]. 
Endothelial dysfunction elicited by oxLDL has been demonstrated as the key step in the initiation of 
AS,  leading  to  lipid  peroxidation  (e.g.,  MDA  production),  apoptotic  cell  generation,  adhesion 
molecules overexpression and reduction of the NO release. Several receptors of oxLDL have been 
identified so far, including SR-AI/II, CD36, SR-BI, FcγRII and LOX-1 expressed by endothelial cells. 
Among  these  receptors,  LOX-1  is  characterized  as  the  major  receptor  for  oxLDL  in  endothelial  
cells  [19],  and  its  inducible  expression  has  been  identified  as  a  major  cause  of  the  endothelial 
dysfunction, leading to the up-regulation of genes related to apoptosis, inflammation, adhesion and 
secretion [20–22]. Increased expression of LOX-1 activates NADPH oxidase (subunit gp91phox), and 
increases the intracellular reactive oxygen species (ROS) generation. Excessive ROS directly results in 
lipid peroxidation (e.g., MDA generation), and is also associated with p38MAPK activation, NF-κB 
translocation  as  well  as  a  proatherosclerotic,  prooxidative,  and  proinflammatory  gene  expression 
pattern,  together  with  accelerated  AS  [23].  The  increase  of  intracellular  ROS  also  attenuated  the 
secretory function of endothelial cells, leading to the reduction of NO release. 
Studies have clearly shown that flavonoids can enter into the circulation intact [24–28]. Flavonoids 
were mainly absorbed and excreted in intact forms and metabolized into methylated derivatives in 
human urine, although there is a rather low bioavailability [29]. Recently, it has been revealed that 
flavonoids could be incorporated into the plasma membrane and cytosol of endothelial cells and may 
be  beneficial  for  scavenging  ROS  [30].  It  is  widely  accepted  that  oxLDL-induced  endothelial Int. J. Mol. Sci. 2011, 12                     
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dysfunction  is  associated  with  an  alteration  of  the  cell  redox  status, thus the  pre-incorporation  of 
flavonoids  by  endothelial  cells  might  enhance  their  resistance  to  the  afterwards  damaging  effects 
resulting from ROS generation induced by oxLDL. Although there is very little knowledge about the 
different bio-absorption and bioavailability of different flavonoids inendothelial cells, it is supposed 
that  the  significant  correlation  between  the  inhibition  of  endothelial  dysfunction  and  intracellular 
radical scavenging activity of flavonoids could be based upon flavonoids incorporation by endothelial 
cells. Thus, it is commonly assumed that flavonoids exert endothelium-protective potency through the 
antioxidant  pathway.  Many  studies  have  focused  on  the  association  of  –OH  moieties  with  the 
antioxidant activity of flavonoids [31–33]. Previous studies demonstrated that hydroxyl groups on the 
B-ring play an important role in electron resonance and in electron donation to the oxidizing agent. 
This is consistent with our finding that the number of –OH in total or in B-ring was closely correlated 
with the inhibitory effects on endothelial dysfunction, suggesting that 4-oxo-flavonoids exerted the 
endothelium-protective potency partially through the antioxidant pathway. However, the antioxidatant 
potential of flavonoids is also affected by the position of –OH substitutions on the A, B or C-ring. 
Previous studies have reported that the torsion angle of B-ring with the rest of flavonoids molecule 
correlates with  its overall scavenging activity [34,35]. Furthermore, the A-ring  has poor reactivity 
toward peroxyl radicals, and it is not a significant contributor to the antiradical activity. Therefore, 
hydroxylation substitution on ring-B and C is important for the antioxidant and antiradical activity of 
flavonoids. Derivatization or substitution of this group probably affects the planarity of the molecule, 
causes B-ring to lose coplanarity to rings A and C, and reduces the potential of these compounds to 
chelate metal ions, thereby preventing the iron-induced peroxidation. Hence, our results showed that 
flavonols  with  3',4'-ortho-dihydroxyl  and  3-hydroxyl  group  exerted  stronger  activity  in  promoting 
endothelial  viability,  decreasing  lipid peroxidation and  inhibiting cell apoptosis.  Among the tested 
flavonols,  myricetin  and  quercetin,  showed  stronger  effect  in  attenuating  the  oxLDL-induced 
endothelial dysfunction, both of which possess a –OH on C3 of C-ring and two –OH moieties on C3' 
and C4' position of B-ring. Our results are also consistent with the published data [31]. 
It is widely recognized that the  induction of endothelium-monocyte adhesion and  inflammatory 
reaction  strongly  depends  on the  activation  of  the  transcription  factor,  NF-κB [36].  Regulation  of  
NF-κB is redox-sensitive due to the modification of critical cysteine residues in the upstream signal 
transducers (in particular protein kinases and phosphatases) and the transcription factors themselves, 
which  may  differentially  affect  their  DNA  binding  capacity  [37].  Extensive  studies  show  that 
flavonoids  may  inhibit NF-κB and other redox-sensitive transcription  factors and hence act as the  
anti-inflammatory agents [38–41]. Our results suggested that some flavonols, flavones and isoflavones, 
showed strong activity in preventing the inflammation molecules in endothelial cells, which might be 
resulted from the presence of 5,7-meta-dihydroxyl groups. This is consistent with the previous study of 
Lotito [42] that the A-ring 5,7-dihydroxyl groups but not the B-ring per se are required for flavonoids 
to inhibit the TNFα-induced adhesion molecules expression in endothelial cells. However, it remains 
unclear how 5,7-dihydroxyl groups was related to the inhibitory effects on endothelial inflammatory. 
The generation of NO by endothelial nitric oxide synthase (eNOS) plays a major role in maintaining 
cardiovascular homeostasis by influencing blood pressure, endothelial dysfunction, vascular smooth 
muscle mitogenesis, matrix synthesis, leukocyte adhesion, and platelet aggregation. The expression of 
eNOS and secretion of NO have been shown to be unregulated by some flavonoids. There is some Int. J. Mol. Sci. 2011, 12                     
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evidence  that  estrogen  receptor  (ER)  is  involved  in  signal  transduction  for  eNOS  expression. 
The  interaction  of  estrogen  with  ER  leads  to  the  transcriptional  activation  of  estrogen-responsive  
genes [43,44], including eNOS [45] and key antioxidant defense genes [46]. In addition to its genomic 
actions, estrogen rapidly stimulates eNOS activity in cultured endothelial cells. Isoflavones, such as 
genistein and daidzein, have also been demonstrated to be the natural ligands for ERs, particularly ERβ 
rather than ERα, which can elicit endothelium-dependent and -independent relaxation in arterial rings 
in vitro and in vivo. Previous studies have revealed that isoflavones are structurally similar to estrogen 
and generally  bind to ERβ with  higher affinity  [47,48].  In our study,  both genistein and daidzein 
showed significant effects on the NO release, which might result from the interaction of isoflavones 
and ER and the downstream regulation of eNOS expression. Therefore, the structural characteristic of 
a B-ring substituted on C3 of C-ring might help activate ER and then enhance the expression of eNOS 
and NO release. 
5. Conclusions 
In  summary,  our  study  revealed  that  3',4'-ortho-dihydroxyl,  3-hydroxyl,  2,3-double  bond  and  
5,7-meta-dihydroxyl  groups  were  the  main  structure  requirements  of  4-oxo-flavonoids  for  the 
protective potency against oxLDL-induced endothelial dysfunction. However, the potential roles of 
such characteristics in relation to the inhibitory effects on endothelial dysfunction might be differential. 
The results of the present study might provide some evidence for AS prevention and help to provide a 
basis  for the  design  of  potent  antiatherosclerotic  agents that  will  have  therapeutic  potential  in  the 
prevention of AS. 
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